BACKGROUND: Type 2 innate lymphoid cells (ILC2s) are relevant players in type 2 asthma. They initiate eosinophil infiltration and airway hyperreactivity (AHR) through cytokine secretion. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an inhibitory receptor considered to be an immune checkpoint in different inflammatory diseases. OBJECTIVE: Our aim here was to investigate the expression of LAIR-1 and assess its role in human and murine ILC2s. METHODS: Wild-type and LAIR-1 knockout mice were intranasally challenged with IL-33, and pulmonary ILC2s were sorted to perform an ex vivo comparative study based on RNA sequencing and flow cytometry. We next studied the impact of LAIR-1 deficiency on AHR and lung inflammation by using knockout mice and adoptive transfer experiments in Rag2-/-Il2rg-/- mice. Knockdown antisense strategies and humanized mice were used to assess the role of LAIR-1 in human ILC2s. RESULTS: We have demonstrated that LAIR-1 is inducible on activated ILC2s and downregulates cytokine secretion and effector function. LAIR-1 signaling in ILC2s was mediated via inhibitory pathways, including SHP1/PI3K/AKT, and LAIR-1 deficiency led to exacerbated ILC2-dependent AHR in IL-33 and Alternaria alternata models. In adoptive transfer experiments, we confirmed the LAIR-1-mediated regulation of ILC2s in vivo. Interestingly, LAIR-1 was expressed and inducible in human ILC2s, and knockdown approaches of Lair1 resulted in higher cytokine production. Finally, engagement of LAIR-1 by physiologic ligand C1q significantly reduced ILC2-dependent AHR in a humanized ILC2 murine model. CONCLUSION: Our results unravel a novel regulatory axis in ILC2s with the capacity to reduce allergic AHR and lung inflammation.
BACKGROUND: Type 2 innate lymphoid cells (ILC2s) are relevant players in type 2 asthma. They initiate eosinophil infiltration and airway hyperreactivity (AHR) through cytokine secretion. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) is an inhibitory receptor considered to be an immune checkpoint in different inflammatory diseases. OBJECTIVE: Our aim here was to investigate the expression of LAIR-1 and assess its role in human and murine ILC2s. METHODS: Wild-type and LAIR-1 knockout mice were intranasally challenged with IL-33, and pulmonary ILC2s were sorted to perform an ex vivo comparative study based on RNA sequencing and flow cytometry. We next studied the impact of LAIR-1 deficiency on AHR and lung inflammation by using knockout mice and adoptive transfer experiments in Rag2-/-Il2rg-/- mice. Knockdown antisense strategies and humanized mice were used to assess the role of LAIR-1 in human ILC2s. RESULTS: We have demonstrated that LAIR-1 is inducible on activated ILC2s and downregulates cytokine secretion and effector function. LAIR-1 signaling in ILC2s was mediated via inhibitory pathways, including SHP1/PI3K/AKT, and LAIR-1 deficiency led to exacerbated ILC2-dependent AHR in IL-33 and Alternaria alternata models. In adoptive transfer experiments, we confirmed the LAIR-1-mediated regulation of ILC2s in vivo. Interestingly, LAIR-1 was expressed and inducible in human ILC2s, and knockdown approaches of Lair1 resulted in higher cytokine production. Finally, engagement of LAIR-1 by physiologic ligand C1q significantly reduced ILC2-dependent AHR in a humanized ILC2 murine model. CONCLUSION: Our results unravel a novel regulatory axis in ILC2s with the capacity to reduce allergic AHR and lung inflammation.
Authors: Ruben J Geerdink; Marije P Hennus; Geertje H A Westerlaken; Alferso C Abrahams; Kim I Albers; Jona Walk; Esther Wesselink; Riny Janssen; Louis Bont; Linde Meyaard Journal: J Allergy Clin Immunol Date: 2017-10-16 Impact factor: 10.793
Authors: Jeoung-Eun Park; David D Brand; Edward F Rosloniec; Ae-Kyung Yi; John M Stuart; Andrew H Kang; Linda K Myers Journal: J Biol Chem Date: 2020-01-13 Impact factor: 5.157
Authors: Gang Liu; Marion A Cooley; Prema M Nair; Chantal Donovan; Alan C Hsu; Andrew G Jarnicki; Tatt Jhong Haw; Nicole G Hansbro; Qi Ge; Alexandra C Brown; Hock Tay; Paul S Foster; Peter A Wark; Jay C Horvat; Jane E Bourke; Chris L Grainge; W Scott Argraves; Brian G Oliver; Darryl A Knight; Janette K Burgess; Philip M Hansbro Journal: J Pathol Date: 2017-12 Impact factor: 7.996
Authors: Emmanuel T Osei; Leila B Mostaço-Guidolin; Aileen Hsieh; Stephanie M Warner; May Al-Fouadi; Mary Wang; Darren J Cole; Geoffrey N Maksym; Teal S Hallstrand; Wim Timens; Corry-Anke Brandsma; Irene H Heijink; Tillie-Louise Hackett Journal: Sci Rep Date: 2020-05-26 Impact factor: 4.379
Authors: Jesse C Nussbaum; Steven J Van Dyken; Jakob von Moltke; Laurence E Cheng; Alexander Mohapatra; Ari B Molofsky; Emily E Thornton; Matthew F Krummel; Ajay Chawla; Hong-Erh Liang; Richard M Locksley Journal: Nature Date: 2013-09-15 Impact factor: 49.962
Authors: Emily Howard; Benjamin P Hurrell; Doumet Georges Helou; Christine Quach; Jacob D Painter; Pedram Shafiei-Jahani; Marshall Fung; Parkash S Gill; Pejman Soroosh; Arlene H Sharpe; Omid Akbari Journal: Front Immunol Date: 2021-08-31 Impact factor: 8.786